EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

A Case Report of Lenacapavir Use in a Patient with Multidrug-Resistant HIV: The First Experience in Asia

Yongseop Lee iD, Ki Hyun Lee iD, Jung Ah Lee iD, Sang Min Ahn iD, Min Han iD, Jun Yong Choi iD

Yonsei Medical Journal · 2024

DOI: 10.3349/ymj.2023.0540 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Yonsei Medical Journal, 2024. Verfasst von Yongseop Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Drug Resistance, Multiple, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Disease Control and Prevention Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lenacapavir is a novel, first-in-class, capsid inhibitor, which has been approved as an adjunctive therapy for multidrug-resistant human immunodeficiency virus (HIV)-1 virus in combination with optimized background regimen (OBR). Lenacapavir has demonstrated a significant decrease in viral load and high rate of virologic suppression in patients with multidrug-resistant HIV-1 infection with limited treatment options. Here, we report a case of 43-year-old male who was diagnosed with HIV-1 infection in 2005 but failed to achieve viral suppression due to multiclass resistance. After lenacapavir use with OBR, viral suppression was achieved, and recovery of CD4+ T-cell count was observed for 8 months. This case report shows the first lenacapavir experience in Asia in a heavily treatment-experienced HIV patient with limited treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1Drug Resistance, Multiple, ViralAnti-HIV AgentsViral LoadHumansMaleAdultCD4 Lymphocyte CountAsia

Stichwörter der Autor:innen

HIVacquired immunodeficiency syndromeanti-retroviral agentsdrug resistance

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • AIDS Research Institute, Yonsei University College of Medicine, Seoul, Korea. seran@yuhs.ac.

ORCID-Profile: Yongseop Lee, Ki Hyun Lee, Jung Ah Lee, Sang Min Ahn, Min Han, Jun Yong Choi

Förderung

  • Korea Disease Control and Prevention Agency

Zitieren

APA

Lee, Y., Lee, K. H., Lee, J. A., Ahn, S. M., Han, M., & Choi, J. Y. (2024). A Case Report of Lenacapavir Use in a Patient with Multidrug-Resistant HIV: The First Experience in Asia. Yonsei Medical Journal. https://doi.org/10.3349/ymj.2023.0540

Vancouver

Lee Y, Lee KH, Lee JA, Ahn SM, Han M, Choi JY. A Case Report of Lenacapavir Use in a Patient with Multidrug-Resistant HIV: The First Experience in Asia. Yonsei Medical Journal. 2024. doi:10.3349/ymj.2023.0540

BibTeX
@article{Lee2024,
  author = {Lee, Yongseop and Lee, Ki Hyun and Lee, Jung Ah and Ahn, Sang Min and Han, Min and Choi, Jun Yong},
  title = {A Case Report of Lenacapavir Use in a Patient with Multidrug-Resistant HIV: The First Experience in Asia},
  journal = {Yonsei Medical Journal},
  year = {2024},
  doi = {10.3349/ymj.2023.0540}
}
Kostenlos starten →